ATE418565T1 - Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden - Google Patents

Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden

Info

Publication number
ATE418565T1
ATE418565T1 AT02715313T AT02715313T ATE418565T1 AT E418565 T1 ATE418565 T1 AT E418565T1 AT 02715313 T AT02715313 T AT 02715313T AT 02715313 T AT02715313 T AT 02715313T AT E418565 T1 ATE418565 T1 AT E418565T1
Authority
AT
Austria
Prior art keywords
receptors
antibodies
diagnosis
cancer
functional
Prior art date
Application number
AT02715313T
Other languages
English (en)
Inventor
Angus Gidley-Baird
Julian Barden
Original Assignee
Intreat Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR2579A external-priority patent/AUPR257901A0/en
Priority claimed from AUPR5890A external-priority patent/AUPR589001A0/en
Priority claimed from AUPR5891A external-priority patent/AUPR589101A0/en
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Application filed by Intreat Pty Ltd filed Critical Intreat Pty Ltd
Application granted granted Critical
Publication of ATE418565T1 publication Critical patent/ATE418565T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
AT02715313T 2001-01-17 2002-01-17 Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden ATE418565T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPR2579A AUPR257901A0 (en) 2001-01-17 2001-01-17 Diagnosis and treatment of malignant lymphoma
AUPR5890A AUPR589001A0 (en) 2001-06-22 2001-06-22 An antibody cancer therapeutic
AUPR5891A AUPR589101A0 (en) 2001-06-22 2001-06-22 Diagnosis of cell cancers using an antibody to non-functionalP2X, receptors
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
ATE418565T1 true ATE418565T1 (de) 2009-01-15

Family

ID=27507500

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08156593T ATE548383T1 (de) 2001-01-17 2002-01-17 Diagnose und behandlung von karzinomen und anderen leiden
AT02715313T ATE418565T1 (de) 2001-01-17 2002-01-17 Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08156593T ATE548383T1 (de) 2001-01-17 2002-01-17 Diagnose und behandlung von karzinomen und anderen leiden

Country Status (14)

Country Link
US (10) US7326415B2 (de)
EP (2) EP1360203B1 (de)
JP (2) JP4384852B2 (de)
CN (2) CN100497385C (de)
AT (2) ATE548383T1 (de)
AU (1) AU2003235005B2 (de)
CA (1) CA2434490C (de)
DE (1) DE60230482D1 (de)
DK (2) DK1961767T3 (de)
ES (2) ES2383712T3 (de)
MY (1) MY158262A (de)
PT (1) PT1360203E (de)
TW (1) TWI319011B (de)
WO (1) WO2002057306A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
CA2434490C (en) 2001-01-17 2014-06-03 Intreat Pty Limited Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
AU2002322192B2 (en) * 2001-09-03 2008-05-01 Biosceptre International Limited Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions
DE60228758D1 (de) * 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
GB0229139D0 (en) * 2002-12-13 2003-01-15 Glaxo Group Ltd Gene polymorphisms
WO2007146061A2 (en) * 2006-06-09 2007-12-21 University Hospitals Of Cleveland Cell collection and disease screening
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
JP5624885B2 (ja) * 2007-09-14 2014-11-12 バイオセプター・インターナショナル・リミテッド 細胞外体液中のプリン作動性（ｐ２ｘ）受容体
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
CA2737126C (en) 2007-09-14 2018-05-01 Biosceptre International Limited Novel p2x7 epitopes
ES2610225T3 (es) * 2008-07-04 2017-04-26 Biosceptre (Aust) Pty Ltd Péptidos y epítopos anti P2X7
DK2370465T3 (da) * 2008-12-19 2019-05-06 Ablynx Nv Genetisk immunisering til fremstilling af immunoglobuliner mod celleassocierede antigener, såsom p2x7, cxcr7 eller cxcr4
ES2557456T3 (es) * 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
US8771693B2 (en) * 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
AU2010336032C1 (en) 2009-12-24 2016-04-21 Biosceptre International Limited Antibodies to non-functional oligomeric P2X7 receptors
CN106310245A (zh) * 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
WO2012149334A2 (en) * 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
US9566318B2 (en) * 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy
WO2017041143A1 (en) 2015-09-11 2017-03-16 Ctm@Crc Ltd. Chimeric antigen receptors and uses thereof
EP3528789A4 (de) * 2016-10-21 2020-06-24 Biosceptre UK Limited Zytotoxische teilchen
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
EP4003531A1 (de) * 2019-07-26 2022-06-01 Biosceptre (Aust) Pty Ltd Gegen p2x7-rezeptor gerichtete therapie
PH12022551621A1 (en) 2020-01-03 2023-10-23 Incyte Corp Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
TWI873265B (zh) 2020-01-03 2025-02-21 美商英塞特公司 抗ｃｄ７３抗體及其用途
KR20230157940A (ko) 2020-12-29 2023-11-17 인사이트 코포레이션 A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법
AU2022253547A1 (en) * 2021-04-08 2023-10-05 Biosceptre (Aust) Pty Ltd Methods for controlling immune cell activity
EP4587464A1 (de) * 2022-09-14 2025-07-23 Biosceptre (Aust) Pty Ltd Verfahren zum nachweis von immunzellen
AU2023343786A1 (en) * 2022-09-14 2025-02-20 Biosceptre (Aust) Pty Ltd In vivo detection of immune cells
EP4587465A1 (de) * 2022-09-14 2025-07-23 Biosceptre (Aust) Pty Ltd Anreicherung von manipulierten immunzellen

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1141314A (en) * 1914-12-19 1915-06-01 Eugene W Caldwell Photographic developing apparatus.
US2191508A (en) * 1939-02-06 1940-02-27 Stuart Robert Photographic film carrier and development receptacle
US3010460A (en) * 1958-07-03 1961-11-28 Geo B Hart Inc Apparatus for wetting absorbent bodies for moistening and supporting plant parts
US3077155A (en) * 1960-08-08 1963-02-12 Pako Corp Device for treating photographic sheet material
US3121438A (en) * 1961-01-16 1964-02-18 Union Carbide Corp Open head container and cover therefor
US3952756A (en) * 1974-06-14 1976-04-27 Purex Corporation Semi automatic parts cleaning machine
US4302273A (en) * 1980-06-04 1981-11-24 Rca Corporation Etching tank in which the solution circulates by convection
US4305413A (en) * 1980-07-25 1981-12-15 Ecology, Inc. Cleaning apparatus
US4550579A (en) * 1984-04-13 1985-11-05 Frank Clifford G Apparatus for the dyeing of shaped articles
US5104727A (en) * 1989-06-16 1992-04-14 W. L. Gore & Associates, Inc. Air bag laminates
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
JPH0756015A (ja) * 1993-08-18 1995-03-03 Sony Corp カラーフィルタの製造方法
EP0760850A1 (de) 1994-05-27 1997-03-12 Glaxo Group Limited P2x REZEPTOREN (PURINOCEPTORENFAMILIE)
US5660640A (en) * 1995-06-16 1997-08-26 Joray Corporation Method of removing sputter deposition from components of vacuum deposition equipment
CA2228999A1 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
EP0907729A1 (de) 1996-04-30 1999-04-14 Smithkline Beecham Plc Splicevarianten des menschlichen p2x4 rezeptors
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US5851307A (en) * 1997-04-28 1998-12-22 Advanced Micro Devices, Inc. Method for in-situ cleaning of polysilicon-coated quartz furnaces
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
US5849091A (en) * 1997-06-02 1998-12-15 Micron Technology, Inc. Megasonic cleaning methods and apparatus
US5906216A (en) * 1997-10-10 1999-05-25 Barlet; Bruce N. Denture cleaning device
EP2080802B1 (de) 1998-06-01 2017-03-29 Agensys, Inc. Neuartige serpentine-transmembran-antigene, die von krebserkrankungen des menschen exprimiert werden, und verwendungen davon
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6055694A (en) * 1998-11-30 2000-05-02 Tsk America, Inc. Wafer scrubbing machine
EP1157038A4 (de) 1999-02-26 2005-01-19 Smithkline Beecham Corp KLONIERUNG EINES P2Y-äHNLICHEN 7TM-REZEPTORS (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (nl) 1999-06-28 2001-01-02 Univ Delft Tech Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten.
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
CA2434490C (en) 2001-01-17 2014-06-03 Intreat Pty Limited Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
AU2002322192B2 (en) 2001-09-03 2008-05-01 Biosceptre International Limited Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions
DK1473367T3 (da) 2003-04-17 2007-10-01 Affectis Pharmaceuticals Ag Midler og fremgangsmåder til diagnosticering og behandling af effektive lidelser
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
US20100036101A1 (en) 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
CA2737126C (en) 2007-09-14 2018-05-01 Biosceptre International Limited Novel p2x7 epitopes
JP5624885B2 (ja) 2007-09-14 2014-11-12 バイオセプター・インターナショナル・リミテッド 細胞外体液中のプリン作動性（ｐ２ｘ）受容体
ES2610225T3 (es) 2008-07-04 2017-04-26 Biosceptre (Aust) Pty Ltd Péptidos y epítopos anti P2X7
ES2557456T3 (es) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
AU2010336032C1 (en) 2009-12-24 2016-04-21 Biosceptre International Limited Antibodies to non-functional oligomeric P2X7 receptors
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy

Also Published As

Publication number Publication date
CA2434490C (en) 2014-06-03
WO2002057306A1 (en) 2002-07-25
DE60230482D1 (de) 2009-02-05
US20090192293A1 (en) 2009-07-30
CN101555283A (zh) 2009-10-14
US7888473B2 (en) 2011-02-15
JP4384852B2 (ja) 2009-12-16
US7531171B2 (en) 2009-05-12
US20040142342A1 (en) 2004-07-22
ATE548383T1 (de) 2012-03-15
DK1360203T3 (da) 2009-04-20
TWI319011B (en) 2010-01-01
CN101555283B (zh) 2012-03-21
HK1123311A1 (en) 2009-06-12
EP1961767B1 (de) 2012-03-07
CN1541222A (zh) 2004-10-27
US8080635B2 (en) 2011-12-20
JP2004528286A (ja) 2004-09-16
US7326415B2 (en) 2008-02-05
US9663584B2 (en) 2017-05-30
US8709425B2 (en) 2014-04-29
HK1138013A1 (en) 2010-08-13
US20150274839A1 (en) 2015-10-01
EP1961767A2 (de) 2008-08-27
US20170327592A1 (en) 2017-11-16
AU2003235005A8 (en) 2003-09-11
US20140323693A1 (en) 2014-10-30
EP1360203A1 (de) 2003-11-12
US20130245226A1 (en) 2013-09-19
CN100497385C (zh) 2009-06-10
AU2003235005A1 (en) 2003-09-11
ES2383712T3 (es) 2012-06-25
EP1360203A4 (de) 2005-06-22
US8399617B2 (en) 2013-03-19
JP2009235074A (ja) 2009-10-15
EP1360203B1 (de) 2008-12-24
US20110092674A1 (en) 2011-04-21
MY158262A (en) 2016-09-30
US20200071419A1 (en) 2020-03-05
US10450380B2 (en) 2019-10-22
HK1070903A1 (zh) 2005-06-30
AU2003235005B2 (en) 2007-09-20
DK1961767T3 (da) 2012-05-29
JP4457169B2 (ja) 2010-04-28
ES2320421T3 (es) 2009-05-22
PT1360203E (pt) 2009-04-03
CA2434490A1 (en) 2002-07-25
EP1961767A3 (de) 2008-10-29
US20080131438A1 (en) 2008-06-05
US20120059151A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
ATE418565T1 (de) Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
ATE306482T1 (de) Amine and amide als ligande für den neuropeptid-y y5 rezeptor, und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
AT500379B8 (de) Tau-proteine
TR200401871T4 (tr) Değiştirilen oktanoil amitlerin (octanoyl amides) hazırlanması
DE69526973D1 (de) Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
ATE423216T1 (de) Neue fructosylpeptidoxidase und deren nutzung
DE69926731D1 (de) Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen
EP1289553A4 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
EP1385421A4 (de) Identifizierung, diagnose und behandlung von neuropathologien, neurotoxizität, tumoren und gehirn- und rückenmarksverletzungen durch mikroelektroden mit mikrovoltammetrie
DE60022754D1 (de) Diagnose und behandlung von arrhythmien
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
DE60223547D1 (de) Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ATE556092T1 (de) Mittel zur diagnose und therapie von ctcl
EP1542721A4 (de) Modifizierte "s" antikörper
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
DE50213398D1 (de) Verwendung bestimmter copolymere als adjuvans und mittel fur den agrotechnischen bereich
DE602004014020D1 (de) Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
NO20000731D0 (no) Neisseria-lactodweeinbindingsprotein
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
DE69900283D1 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
EA200501259A1 (ru) Комбинированное применение фибрата и орлистата для лечения ожирения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1360203

Country of ref document: EP

EEIH Change in the person of patent owner